Category: Markets
Published: 2026-07-07T14:02:55.000Z
Gilead Sciences Inc. (GILD) stock rallied 3.5% after its cancer drug, Trodelvy, received FDA clearance and EU approval for first-line treatment of advanced triple-negative breast cancer, both as a monotherapy and in combination with Merck's Keytruda. HSBC upgraded GILD to Buy with a $155 target, citing underappreciated HIV therapy advancements and the new oncology catalysts. The company also reported strong financial performance with significant revenue, gross margins, and free cash flow.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.